TLDRs:
- Plus Therapeutics prices a $15M upsized public offering at $0.38 per unit.
- Units include common shares and five-year warrants exercisable immediately.
- The underwriter receives a 30-day option to cover potential overallotments.
- Proceeds target working capital and general corporate needs.
- Offering supports liquidity as the company advances CNS-focused programs.
Plus Therapeutics shares traded around $0.36 as the company completed an upsized public offering. The transaction raised fresh capital and reinforced the company’s short-term liquidity position. As a result, the offering placed balance sheet strength at the center of investor focus.
Plus Therapeutics Prices $15M Upsized Public Offering
Plus Therapeutics priced an upsized underwritten public offering totaling about $15 million in gross proceeds. The company sold 39,473,684 units to the public at $0.38 per unit. Each unit consisted of one common share and one immediately exercisable warrant.
The warrant carries an exercise price equal to the unit price of $0.38 per share. It also features a five-year term from the date of issuance. This structure blended immediate equity funding with potential future capital access.
Lake Street Capital Markets served as the sole underwriter for the transaction. The registration statements supporting the offering became effective on January 13, 2026. Accordingly, the offering is scheduled to close on January 15, 2026, subject to standard conditions.
Offering Terms and Capital Allocation Strategy
The underwriter received a 30-day option to purchase additional securities. This option covers up to 5,921,052 shares, warrants, or a combination of both. Such flexibility supports market demand and potential overallotment coverage.
Plus Therapeutics intends to use the net proceeds for working capital needs. The company also plans to fund general corporate purposes with the raised capital. These uses support operational continuity and internal financial flexibility. The offering followed an upsized structure compared with earlier expectations. Management aligned pricing with prevailing market conditions and funding objectives. The transaction emphasized balance sheet support rather than expansion-driven spending.
Business Context and Corporate Background
Plus Therapeutics operates as a clinical-stage healthcare company based in Houston, Texas. The company focuses on precision diagnostics and radiopharmaceuticals for CNS cancers. Its programs target complex and difficult-to-treat neurological oncology conditions.
The development pipeline includes lead candidates for leptomeningeal metastases and recurrent glioblastoma. These indications represent areas with limited treatment options and high unmet needs. The company maintains a focused research and development strategy.
CNSide Diagnostics functions as a wholly owned subsidiary of Plus Therapeutics. The unit develops proprietary laboratory tests designed to detect tumor cells in the central nervous system. Together, these platforms define the company’s integrated diagnostic and therapeutic approach.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
